What is an expected outcome of including diverse populations in clinical trials?

Including diverse populations in clinical trials is crucial for generating data that accurately reflects the variability found in the general population. This approach ensures that the findings are more generalizable and applicable to a broader spectrum of patients. As a result, regulatory agencies can make more informed decisions based on comprehensive evidence that accounts for different demographics, including race, ethnicity, age, and gender.

When clinical trials only include homogenous populations, the safety and efficacy findings may not translate well to the general population, leading to potential pitfalls in treatment recommendations and interventions. By incorporating diverse groups, the data captured can highlight unique responses to treatments, leading to better understanding of how therapies perform across different segments of the population. This ultimately supports more equitable healthcare and better regulatory decisions concerning drug approvals and recommendations.

While including diverse populations can also have other potential benefits, such as fostering trust and improving the overall integrity of research, the primary expected outcome directly connected to regulatory decision-making is the creation of more representative data. This is why the option referring to more representative data leading to better regulatory decisions is the most accurate choice.